Page last updated: 2024-09-04

ezetimibe and Obesity

ezetimibe has been researched along with Obesity in 35 studies

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (37.14)29.6817
2010's22 (62.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chang, Y; Chen, YG; Ji, XP; Li, CB; Li, XX; Liu, BS; Xu, F; Zhang, C; Zhao, L1
Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H1
Adachi, H; Bekki, H; Honma, T; Nakano, H; Nakata, M; Nohara, M; Yamamoto, K; Yoshiyama, H1
Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe1
Chang, E; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ1
Dalbøge, LS; Fabricius, K; Hansen, G; Hansen, HB; Jelsing, J; Pedersen, PJ; Vrang, N1
Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM1
Chung, RT; Corey, KE; Giugliano, R; Simon, TG1
Frydrychowicz, C; Mueller, W; Pasieka, B; Petros, S; Pierer, M; Weidhase, L1
Lüscher, TF1
Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE1
Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD1
Dallinga-Thie, GM; Hajer, GR; van Vark-van der Zee, LC; Visseren, FL1
Camarota, LM; Davies, JP; Gilham, DE; Howles, PN; Hui, DY; Ioannou, YA; Jandacek, RJ; Labonté, ED; Rojas, JC; Tso, P1
de Bree, P; Doevendans, PA; Hajer, GR; Hoefer, IE; Olijhoek, JK; Rafii, S; Verhaar, MC; Visseren, FL; Westerweel, PE1
Díaz Gómez, JM1
Derdemezis, CS; Elisaf, MS; Filippatos, TD; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD1
Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES1
Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A1
Hasegawa, K; Hiramitsu, S; Hishida, H; Ishiguro, Y; Kani, A; Kato, K; Matsubara, Y; Matsuyama, H; Noba, M; Ozaki, Y; Uemura, A; Yamada, K; Yoshida, S1
Barrett, PH; Chan, DC; Gan, SK; Ooi, EM; Watts, GF1
Enjoji, M; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Matsunaga, K; Nakamuta, M; Nakashima, M1
Agouridis, AP; Bairaktari, ET; Elisaf, MS; Filippatos, TD; Kostara, C; Nakou, ES1
Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lund, BP; Rieck, AE; Rossebø, AB1
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O1
Betters, JL; Jia, L; Yu, L1
Arai, H; Matsubara, T; Minami, M; Murayama, T; Tamura, Y; Yokode, M1
Inazumi, K; Kawakami, C; Kikuchi, K; Koike, H; Miyazaki, T; Nezu, U; Ono, K; Orime, K; Sato, K; Sato, M; Shirakawa, J; Terauchi, Y; Wakasugi, T; Watanabe, S; Yamakawa, T1
González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E; Ramos-Zavala, MG1
Devaraj, S; Jialal, I1
Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M1
Cook, J; Davis, H; Hoos, L; Hwa, JJ; Tetzloff, G; van Heek, M; Zheng, S1
Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van Vark-van der Zee, LC; Visseren, FL1
Austin, TM; Cook, JA; Davis, HR; Farley, C; Tetzloff, GG; van Heek, M1

Reviews

3 review(s) available for ezetimibe and Obesity

ArticleYear
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia

2016
[Cardiovascular mortality in kidney transplatation].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28 Suppl 5

    Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Comorbidity; Coronary Angiography; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Humans; Kidney Diseases; Kidney Transplantation; Myocardial Ischemia; Obesity; Postoperative Complications; Preoperative Care; Prognosis; Risk Factors

2008
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
    Annual review of physiology, 2011, Volume: 73

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biliary Tract; Biological Transport; Carrier Proteins; Cholesterol; Endocytosis; Ezetimibe; Fatty Liver; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Membrane Proteins; Membrane Transport Proteins; Mice; Obesity; Phytosterols; Primates

2011

Trials

16 trial(s) available for ezetimibe and Obesity

ArticleYear
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
    Lipids in health and disease, 2013, Jul-16, Volume: 12

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult

2013
Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.
    Lipids in health and disease, 2015, Jan-10, Volume: 14

    Topics: Atherosclerosis; Biomarkers; Drug Therapy, Combination; Ezetimibe; Female; Hepatocyte Growth Factor; Humans; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Obesity

2015
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Single-Blind Method; Time Factors; Treatment Outcome; Viral Load; Virus Internalization

2016
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Current medical research and opinion, 2008, Volume: 24, Issue:7

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Mass Index; Caloric Restriction; Cholesterol, LDL; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; gamma-Glutamyltransferase; Homeostasis; Humans; Hypercholesterolemia; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Treatment Outcome; Uric Acid

2008
The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
    Atherosclerosis, 2009, Volume: 202, Issue:1

    Topics: Adolescent; Adult; Aged; Azetidines; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin

2009
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.
    European heart journal, 2008, Volume: 29, Issue:22

    Topics: Anticholesteremic Agents; Azetidines; Cross-Over Studies; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Ezetimibe; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin; Stem Cells

2008
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:18

    Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Aryldialkylphosphatase; Azetidines; Body Mass Index; Cholesterol, HDL; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Lactones; Linear Models; Lipoproteins, HDL2; Lipoproteins, HDL3; Male; Middle Aged; Obesity; Orlistat; Phospholipases A2; Time Factors; Treatment Outcome

2008
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
    Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:4

    Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant

2009
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
    Angiology, 2010, Volume: 61, Issue:4

    Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2010
The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia.
    Journal of atherosclerosis and thrombosis, 2010, Volume: 17, Issue:1

    Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Middle Aged; Obesity; Risk Factors; Triglycerides

2010
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
    Diabetes care, 2010, Volume: 33, Issue:5

    Topics: Adipokines; Aged; alpha-2-HS-Glycoprotein; Anticholesteremic Agents; Apolipoprotein B-100; Azetidines; Biomarkers; Blood Proteins; Body Composition; C-Reactive Protein; Combined Modality Therapy; Diet, Reducing; Ezetimibe; Fatty Liver; Humans; Insulin Resistance; Liver; Middle Aged; Obesity; Patient Compliance; Triglycerides; Weight Loss

2010
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
    Lipids, 2010, Volume: 45, Issue:5

    Topics: Anti-Obesity Agents; Anticholesteremic Agents; Apolipoprotein C-II; Apolipoprotein C-III; Azetidines; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Triglycerides

2010
Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
    The American journal of cardiology, 2010, May-15, Volume: 105, Issue:10

    Topics: Aged; Aged, 80 and over; Angiography; Aortic Valve Stenosis; Azetidines; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Multivariate Analysis; Obesity; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Simvastatin; Stroke Volume; Systole; Treatment Outcome

2010
Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.
    Journal of atherosclerosis and thrombosis, 2012, Volume: 19, Issue:12

    Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind Method; Ezetimibe; Glucose; Humans; Hyperglycemia; Hyperlipidemias; Intestinal Mucosa; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Placebos; Postprandial Period; Prospective Studies; Time Factors; Triglycerides

2012
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
    Cardiovascular drugs and therapy, 2006, Volume: 20, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Azetidines; Blood Glucose; Blood Pressure Determination; Body Mass Index; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Ezetimibe; Female; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Obesity; Time Factors; Treatment Outcome

2006
Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Clinical endocrinology, 2008, Volume: 69, Issue:6

    Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Combinations; Ezetimibe; Fasting; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin

2008

Other Studies

16 other study(ies) available for ezetimibe and Obesity

ArticleYear
Ezetimibe prevents myocardial remodeling in an obese rat model by inhibiting inflammation.
    Acta biochimica Polonica, 2018, Volume: 65, Issue:3

    Topics: Animals; Anticholesteremic Agents; Blotting, Western; C-Reactive Protein; Cardiomegaly; Collagen; Diet, High-Fat; Ezetimibe; Heart; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Myocardium; Obesity; p38 Mitogen-Activated Protein Kinases; Rats, Sprague-Dawley; Vascular Cell Adhesion Molecule-1; Ventricular Remodeling

2018
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
    Heart and vessels, 2019, Volume: 34, Issue:6

    Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides

2019
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2014, Volume: 67, Issue:2 Pt 2

    Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; Essential Hypertension; Ezetimibe; Fosinopril; Humans; Hypertension; Non-alcoholic Fatty Liver Disease; Obesity; Vascular Diseases

2014
Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
    World journal of gastroenterology, 2015, Jul-07, Volume: 21, Issue:25

    Topics: Animals; Anticholesteremic Agents; Autophagy; Biomarkers; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Fatty Liver; Gene Expression Regulation; Hepatocytes; Lipids; Liver; Macrolides; Male; Obesity; Palmitic Acid; Rats, Inbred OLETF; RNA, Messenger

2015
A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Animals; Anti-Obesity Agents; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cricetinae; Diet, High-Fat; Eating; Ezetimibe; Hypoglycemic Agents; Hypolipidemic Agents; Linagliptin; Male; Mesocricetus; Neuropeptides; Obesity; Peptide Fragments; Peptide YY

2015
Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report.
    Journal of medical case reports, 2017, Jan-04, Volume: 11, Issue:1

    Topics: Acute Kidney Injury; Aged; Colchicine; Ezetimibe; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Obesity; Rhabdomyolysis; Simvastatin; Treatment Outcome

2017
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    European heart journal, 2016, Dec-21, Volume: 37, Issue:48

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Obesity; PCSK9 Inhibitors; Testosterone

2016
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
    Journal of lipid research, 2017, Volume: 58, Issue:4

    Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides

2017
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice.
    American journal of physiology. Gastrointestinal and liver physiology, 2008, Volume: 295, Issue:4

    Topics: Animals; Azetidines; Diabetes Mellitus; Dietary Carbohydrates; Dietary Fats; Ezetimibe; Fatty Acid Transport Proteins; Fatty Acids; Female; Hyperglycemia; Intestinal Absorption; Male; Membrane Transport Proteins; Mice; Obesity

2008
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
    Lipids in health and disease, 2010, Mar-12, Volume: 9

    Topics: Adipokines; Adult; Anticholesteremic Agents; Azetidines; Carbohydrates; Cholesterol; Ezetimibe; Fatty Liver; Female; Humans; Liver; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Ursodeoxycholic Acid

2010
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:1

    Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides

2010
Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
    Journal of atherosclerosis and thrombosis, 2012, Volume: 19, Issue:7

    Topics: Adiponectin; Adiposity; Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blotting, Western; Body Weight; Creatinine; Diabetic Nephropathies; Ezetimibe; Glomerular Filtration Rate; Inflammation; Kidney Function Tests; Lipid Metabolism; Male; Metabolism, Inborn Errors; Mice; Mice, Obese; Obesity; Oxidative Stress; Real-Time Polymerase Chain Reaction; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger

2012
Therapy and clinical trials.
    Current opinion in lipidology, 2007, Volume: 18, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Metabolic Syndrome; Models, Biological; Obesity; Risk Factors

2007
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
    FEBS letters, 2007, Dec-11, Volume: 581, Issue:29

    Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors

2007
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    European journal of pharmacology, 2008, Apr-14, Volume: 584, Issue:1

    Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Azetidines; Cholesterol Esters; Cholesterol, Dietary; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Ezetimibe; Fatty Liver; Hepatomegaly; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Obesity; Time Factors; Triglycerides

2008
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
    Diabetes, 2001, Volume: 50, Issue:6

    Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Ezetimibe; Hypercholesterolemia; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Liver; Mesocricetus; Obesity; Triglycerides

2001